Cas No.: | 1243259-19-9 |
Chemical Name: | LM11A-31 HCl |
Synonyms: | LM11A-31 BHS |
SMILES: | Cl.NC(C(C)CC)C(NCCN1CCOCC1)=O |
Formula: | C12H27Cl2N3O2 |
M.Wt: | 316.267 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | LM11A-31 dihydrochloride, a p75NTR (neurotrophin receptor p75) Ligand, is a potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is a water-soluble, non-peptide with high blood-brain barrier permeability[1][2]. |
Target: | proNGF[1] |
In Vivo: | LM11A-31 (oral gavage; 50 mg kg/day for 4 weeks) significantly mitigates proNGF accumulation and preserves BRB integrity[1]. LM11A-31 (orally; 50 or 75 mg/kg) administered for 3 months starting at 6-8 months of age prevents and/or reverses atrophy of basal forebrain cholinergic neurites and cortical dystrophic neurites in mid-stage male APPL/S mice[2]. Animal Model: Male C57BL/6 J mice[1] Dosage: 50 mg kg/day Administration: Oral gavage; for 4 weeks Result: Mitigated proNGF accumulation and preserved BRB integrity. |
References: | [1]. Elshaer SL, et al. Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinalvascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500. [2]. Simmons DA, et al. A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One. 2014 Aug 25;9(8):e102136. |